Caveolin-1 expression in clinically confined human prostate cancer: A novel prognostic marker

Cancer Research

Volumn 59, Issue 22, 1999, Pages 5719-5723

  Yang, Guang ^a   Truong, Luan D ^a   Wheeler, Thomas M ^a   Thompson, Timothy C ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN;

ADULT; ARTICLE; DISEASE COURSE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; SCORING SYSTEM;

ADULT; AGED; CAVEOLIN 1; CAVEOLINS; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM, RESIDUAL; PROGNOSIS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 0033571471     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Catalona, W. J., Smith, D. S., Ratliff, T. L., and Basler, J. W. Detection of organconfined prostate cancer is increased through prostate-specific antigen-based screening. J. Am. Med. Assoc., 270: 948-954, 1993.
2. Epstein, J. I., Walsh, P. C., Carmichael, M., and Brendler, C. B. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. J. Am. Med. Assoc., 271: 368-374, 1994.
3. Albersen, P. C., Fryback, D. G., Storer, B. E., Kolon, T. F., and Fine, J. Long-term survival among men with conservatively treated localized prostate cancer. J. Am. Med. Assoc., 274: 625-631, 1995.
4. Chodak, G. W., Thisted, R. A., Gerber, G. S., Johansson, J., Adolfsson, J., Jones, G. W., Chilsholm, G. D., Moskovitz, B., Livne, P. M., and Warner, J. Results of conservative management of clinically localized prostate cancer. N. Engl. J. Med., 330: 242-248, 1994.
5. Partin, A. W., Kattan, M. W., Subong, E. N., Walsh, P. C, Wojno, K. J., Oesterling, J. E., Scardino, P. T., and Pearson, J. D. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. J. Am. Med. Assoc., 277: 1445-1451, 1997.
6. Partin, A. W., Yoo, J., and Carter, H. B. The use of prostate-specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J. Urol., 150: 110-114, 1993.
7. Kattan, M. W., Eastham, J. A., Stapleton, A. M. F., and Scardino, P. T. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J. Natl. Cancer Inst., 90: 766-771, 1998.
8. Scardino, P. T., Weaver, R., and Hudson, M. A. Early detection of prostate cancer. Hum. Pathol., 23: 211-222, 1992.
9. Yang, G., Truong, L. D., Timme, T. L., Ren, C., Wheeler, T. M., Park, S. H., Nasu, Y., Bangma, C. H., Kattan, M. W., Scardino, P. T., and Thompson, T. C. Elevated expression of caveolin is associated with prostate and breast cancer. Clin. Cancer Res., 4: 1873-1880, 1998.
10. Harter, T., and Simons, K. Caveolae, DIGs, and dynamics of sphingolipid-cholesterol microdomains. Curr. Opin. Cell Biol., 9: 534-542, 1997.
11. Nasu, Y., Timme, T. L., Yang, G., Bangma, C. H., Li, L., Ren, C., Park, S. H., Deleon, M., Wang, J., and Thompson, T. C. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat. Med., 4: 1062-1064, 1998.
12. Lavie, Y., Fiucci, G., and Liscovitch, M. Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. J. Biol. Chem., 273: 32380-32383, 1998.
13. Yang, C. P., Galbiati, F., Volonte, D., Horwitz, S. B., and Lisanti, M. P. Upregulation of caveolin-1 and caveolae organelles in Taxol-resistant A549 cells. FEBS Lett., 439: 368-372, 1998.
14. Wheeler, T. M., and Lebovitz, R. M. Fresh tissue harvest for research from prostatectomy specimens. Prostate, 25: 274-279, 1994.
15. Schroder, F. H., Denis, H. L., Gospodarowicz, F. M. K., and Pavone-Macaluso, M. The TNM classification of prostate cancer. Prostate, 4 (Suppl.): 129-138, 1992.
16. Wheeler, T. M., Dillioglugil, O., Kattan, M. W., Arakawa, A., Soh, S., Suyama, K., Ohori, M., and Scardino, P. T. Clinical and pathologic significance of the level and extent of capsular invasion in clinical stage T12 prostate cancer. Hum. Pathol., 29: 856-862, 1998.
17. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. Am. Stat. Assoc. J., 53: 457-481, 1958.
18. Cox, D. R. Regression models and life tables. J. R. Stat. Soc., B34: 187-220, 1972.
19. Parker, S. L., Tong, T., Bolden, S., and Wingon, P. A. Cancer statistics, 1996. Atlanta: American Cancer Society, 1996.
20. Ohori, M., Goad, J. R., Wheeler, T. M., Eastham, J. A., Thompson, T. C., and Scardino, P. T., Can radical prostateclomy alter the progression poorly differentiated prostate cancer? J. Urol., 152: 1843-1849, 1994.
21. Gervasi, L. A., Mata, J. A., and Scardino, P. T. The prognostic significance of the extent of nodal metastases in prostatic cancer. J. Urol., 142: 332-336, 1989.
22. Lerner, S. P., Seale-Hawkins, C., Carlton, C. E., and Scardino, P. T. The risk of dying of prostate cancer in patients with clinically localized disease. J. Urol., 146: 1040-1045, 1991.
23. Thompson, T. C., Timme, T. L., and Sehgal, I. Oncogenes, growth factors and hormones in prostate cancer. In: R. B. Dickson and D. S. Salomon (eds.), Hormones and Growth Factors in Development and Neoplasia, pp. 327-359. New York: John Wiley & Sons, Inc., 1998.
24. Shibata, A., and Whittemore, A. Genetic predisposition to prostate cancer: possible explanations for ethnic differences in risk. Prostate, 32: 65-72, 1997.
25. Freeman, V. L., Leszczak, J., and Cooper, R. S. Race and the histologic grade of prostate cancer. Prostate, 30: 79-84, 1997.
26. Byar, D. P., and Mostofi, F. K. Carcinoma of the prostate: prognostic evaluation of certain pathologic features in 208 radical prostatectomies. Examined by the stepsection technique. Cancer (Phila.), 30: 5-13, 1972.
27. Greene, D. R., Egawa, S., Neerhut, G., Glanagan, W., Wheeler, T. M., and Scardino, P. T. The distribution of residual cancer in radical prostatectomy specimens in stage A prostate cancer. J. Urol., 145: 324-329, 1991.